Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

SIMPLE SUMMARY: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative option for high-risk hematologic malignancies. However, disease recurrence after allo-HSCT remains a critical issue, underlining the need to develop maintenance therapy. In this context, NK cell-based immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Devillier, Raynier, Calmels, Boris, Guia, Sophie, Taha, Mohammed, Fauriat, Cyril, Mfarrej, Bechara, Venton, Geoffroy, Vivier, Eric, Olive, Daniel, Chabannon, Christian, Blaise, Didier, Ugolini, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198961/
https://www.ncbi.nlm.nih.gov/pubmed/34071607
http://dx.doi.org/10.3390/cancers13112673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198961/
https://www.ncbi.nlm.nih.gov/pubmed/34071607
http://dx.doi.org/10.3390/cancers13112673

Ejemplares similares